• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

PALB2 mutations shown to be important risk factor for breast cancer

byTomi JunandXu Gao
August 6, 2014
in Chronic Disease, Genetics, Obstetrics, Oncology
Reading Time: 3 mins read
Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis
Share on FacebookShare on TwitterShare on LinkedIn

1. Women with PALB2 mutations were 4 to 9 times more likely to be diagnosed with breast cancer when compared to the general population. 

2. About a third of women with PALB2 mutations developed breast cancer by the age of 70.

Evidence Rating Level: 2 (Good)

Study Rundown: PALB2 encodes a protein that is essential to BRCA2 function and that has been shown to interact with BRCA1. Loss-of-function mutations in PALB2 have been associated with increased risk of breast cancer. This study, involving multiple centers around the world, is one of the largest effort to date to estimate the cancer risk associated with PALB2 loss-of-function mutations.

This study examined over 300 women from families with this mutation to determine how much the PALB2 mutation contributes to breast cancer risk. The results show that PALB2 mutations place women at high risk of breast cancer. Depending on age, women with these mutations had an approximately 4 to 9 times increased risk of breast cancer compared to the general population. By age 70, these women had a 35% risk of developing breast cancer; this risk was as high 58% in women who have family members with breast cancer. For comparison, the risk of breast cancer by age 70 in women with BRCA1 and BRCA2 mutations is about 49 to 57%.

Click to read the study, published today in NEJM

RELATED REPORTS

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Click to read the accompanying editorial in NEJM

Relevant Reading: Meta-Analysis of BRCA1 and BRCA2 Penetrance

In-Depth [retrospective cohort]: The study includes 362 subjects: 311 women and 51 men with confirmed PALB2 mutations. Among these subjects, 229 of the women and 7 of the men had breast cancer. Based on their data, the authors were able to estimate age-specific risk for PALB2 mutation carriers. The annual incidence of breast cancer ranged from 0.01% per year among 20-24 year-olds to 1.34% per year among 70-74 year-olds. The relative risk of breast cancer was highest in the youngest age group, 9.01 (95% confidence interval), and lowest in the oldest age group 4.56 (95% confidence interval). A family history of breast cancer also increased risk, especially having a mother and a sister who developed breast cancer by age 50.

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Breast CancerPALB2
Previous Post

ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

Next Post

Crowdsourcing picture based food ratings comparable to expert ratings

RelatedReports

A middle-aged woman looks thoughtfully at an abstract representation of cells and a statin pill, symbolizing breast cancer and medication usage.
Oncology

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

October 5, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Weekly Rewinds

2 Minute Medicine Rewind August 10, 2026

August 10, 2026
Next Post
Crowdsourcing picture based food ratings comparable to expert ratings

Crowdsourcing picture based food ratings comparable to expert ratings

Corticosteroids and physical therapy equally effective for shoulder impingement syndrome

Corticosteroids and physical therapy equally effective for shoulder impingement syndrome

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients

Novel mTOR inhibitor may prolong heart transplant survival in mice

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer
  • Stool biomarkers may be effective in the evaluation of necrotizing enterocolitis in preterm infants
  • Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer in interim phase 3 results
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.